Table 5_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.docx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Table 3_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.docx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Table 7_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.xlsx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Table 6_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.xlsx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Table 1_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.docx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Table 2_Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.xlsx by Lu An (3432230)

“…Long-term exposure to particulate matter (PM)2.5 and PM10 is associated with a substantial decrease in ovarian reserve, while heavy metals (e.g., lead and cadmium) also demonstrate reproductive toxicity. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”